1. Home
  2. AKRO vs CON Comparison

AKRO vs CON Comparison

Compare AKRO & CON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • CON
  • Stock Information
  • Founded
  • AKRO 2017
  • CON 1979
  • Country
  • AKRO United States
  • CON United States
  • Employees
  • AKRO N/A
  • CON N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • CON
  • Sector
  • AKRO Health Care
  • CON
  • Exchange
  • AKRO Nasdaq
  • CON NYSE
  • Market Cap
  • AKRO 3.5B
  • CON 2.8B
  • IPO Year
  • AKRO 2019
  • CON 2024
  • Fundamental
  • Price
  • AKRO $40.48
  • CON $21.70
  • Analyst Decision
  • AKRO Strong Buy
  • CON Strong Buy
  • Analyst Count
  • AKRO 9
  • CON 7
  • Target Price
  • AKRO $76.29
  • CON $29.00
  • AVG Volume (30 Days)
  • AKRO 938.9K
  • CON 842.8K
  • Earning Date
  • AKRO 05-09-2025
  • CON 03-03-2025
  • Dividend Yield
  • AKRO N/A
  • CON 0.58%
  • EPS Growth
  • AKRO N/A
  • CON N/A
  • EPS
  • AKRO N/A
  • CON 1.46
  • Revenue
  • AKRO N/A
  • CON $1,900,192,000.00
  • Revenue This Year
  • AKRO N/A
  • CON $9.09
  • Revenue Next Year
  • AKRO N/A
  • CON $6.61
  • P/E Ratio
  • AKRO N/A
  • CON $14.70
  • Revenue Growth
  • AKRO N/A
  • CON 3.38
  • 52 Week Low
  • AKRO $17.86
  • CON $18.89
  • 52 Week High
  • AKRO $58.40
  • CON $24.81
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 36.69
  • CON N/A
  • Support Level
  • AKRO $41.84
  • CON N/A
  • Resistance Level
  • AKRO $45.38
  • CON N/A
  • Average True Range (ATR)
  • AKRO 1.98
  • CON 0.00
  • MACD
  • AKRO -0.40
  • CON 0.00
  • Stochastic Oscillator
  • AKRO 16.39
  • CON 0.00

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About CON CONCENTRA GROUP HOLDINGS PARENT INC

Concentra Group Holdings Parent Inc is a provider of occupational health services in the United States. The business is organized into three operating segments: occupational health centers, onsite health clinics, and other businesses.

Share on Social Networks: